Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014
Progressive Multifocal Leukoencephalopathy in Patients with Sarcoidosis
Neurol 82:1307-1313, Jamilloux, Y.,et al, 2014
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Opportunistic Infections of the Retina in Patients with Aquaporin-4 Antibody Disease
JAMA Neurol 71:1429-1432, George, J.S.,et al, 2014
Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Sarcoidosis
Adams & Victors Principles of Neurology, Chp 32, pg 721, Ropper, A.H.,et al, 2014
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Treatment of Behcets Disease
UpToDate, Jan, Smith, E.L. & Yazici, Y., 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Adult Primary Central Nervous System Vasculitis
Lancet 380:767-777, Salvarani, C.,et al, 2012
Clinicopathologic Conference, Paraneoplastic Stiff Person Syndrome with Limbic Encephalitis with Anti-Amphiphysin Antibodies with Metastatic Carcinoma of Breast
NEJM 367:851-861, Case 27-2012, 2012
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Progressive Multifocal Leukoencephalopathy in Transplant Recipients
Ann Neurol 70:305-322, Mateen, F.J.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Headache in Transplant Patients
www.medlink.com, Aug, Lai, T.H., 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Periarteritis Nodosa
www.MedLink.com, June, Ramachandran, T. & Roos, R., 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
Juvenile Dermatomyositis and Other Idiopathic Inflammatory Myopathies of Childhood
Lancet 371:2201-2212, Feldman,B.M.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
Whipples Disease
NEJM 356:55-66, Fenollar,F.,et al, 2007
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Vascultic Neuropathies: An Update
The Neurologist 13:12-19, Gorson,K.C., 2007
Clinical Manifestations and Treatment of Rheumatoid Pachymeningitis
Neurol 68:1079-1080, Starosta,M.A. &Brandwein,S.R., 2007
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
NEJM 354:980-982, Ozcan,C.,et al, 2006